- Home
- DAVA vs SION Comparison
DAVA vs SION Comparison
Compare DAVA & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- SION
- Stock Information
- Founded
- DAVA 2000
- SION 2019
- Country
- DAVA United Kingdom
- SION United States
- Employees
- DAVA N/A
- SION N/A
- Industry
- DAVA EDP Services
- SION
- Sector
- DAVA Technology
- SION
- Exchange
- DAVA Nasdaq
- SION NYSE
- Market Cap
- DAVA 885.9M
- SION 871.7M
- IPO Year
- DAVA 2018
- SION 2025
- Fundamental
- Price
- DAVA $14.94
- SION $19.10
- Analyst Decision
- DAVA Buy
- SION Strong Buy
- Analyst Count
- DAVA 9
- SION 1
- Target Price
- DAVA $25.33
- SION $32.00
- AVG Volume (30 Days)
- DAVA 690.5K
- SION 274.0K
- Earning Date
- DAVA 09-18-2025
- SION 08-25-2025
- Dividend Yield
- DAVA N/A
- SION N/A
- EPS Growth
- DAVA N/A
- SION N/A
- EPS
- DAVA 0.40
- SION N/A
- Revenue
- DAVA $1,007,631,882.00
- SION N/A
- Revenue This Year
- DAVA $6.33
- SION N/A
- Revenue Next Year
- DAVA N/A
- SION N/A
- P/E Ratio
- DAVA $37.59
- SION N/A
- Revenue Growth
- DAVA 5.95
- SION N/A
- 52 Week Low
- DAVA $13.12
- SION $7.26
- 52 Week High
- DAVA $34.94
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- DAVA 52.68
- SION N/A
- Support Level
- DAVA $13.30
- SION N/A
- Resistance Level
- DAVA $15.20
- SION N/A
- Average True Range (ATR)
- DAVA 0.59
- SION 0.00
- MACD
- DAVA 0.17
- SION 0.00
- Stochastic Oscillator
- DAVA 81.39
- SION 0.00
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.